Who is sponsoring NCT03906617?

NCT03906617 is sponsored by The Cooper Health System.

What drugs are being tested in NCT03906617?

Interventions in NCT03906617: Intercostal nerve block and wound infiltration with liposomal bupivacaine, Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone.

What condition does NCT03906617 study?

NCT03906617 studies Robotic Lung Surgery.

Is NCT03906617 still recruiting?

NCT03906617 is currently recruiting now. Last updated 12 November 2021.

Last reviewed 2021-11-12 · How we verify

NCT03906617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

Recruiting now Phase 4 Last updated 12 November 2021

What this trial tests

Phase 4 trial testing Intercostal nerve block and wound infiltration with liposomal bupivacaine in Robotic Lung Surgery in 34 participants. Currently enrolling.

Timeline

10 April 2019

Primary endpoint
10 April 2022

10 June 2022

Quick facts

Lead sponsor	The Cooper Health System
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	34
Start date	10 April 2019
Primary completion	10 April 2022
Estimated completion	10 June 2022
Sites	1 location across United States

Drugs / interventions tested

Intercostal nerve block and wound infiltration with liposomal bupivacaine — full drug profile →
Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone — full drug profile →

Conditions studied

Robotic Lung Surgery — all drugs for Robotic Lung Surgery →

Sponsor

The Cooper Health System — full company profile →

Who can join

Adults 18 to 90, any sex, with Robotic Lung Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The Cooper Health System trials

Trials by the same sponsor.

NCT07296120 — RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients · Phase 4 · not yet recruiting
NCT07042048 — Placing External Ventricular Drains Using Assistive Augmented Reality or Image-Based Localization · NA · not yet recruiting
NCT06462781 — Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1 · Phase 1 · completed
NCT05974423 — Randomized Trial of Narcotic vs Non-Narcotic Pain Modulation After Labrum Repair · Phase 4 · unknown
NCT06398366 — Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03906617 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Cooper Health System
Last refreshed: 12 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03906617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing